Germany's Merz Pharmaceuticals to acquire BioForm Medical for $253 million
04 Jan 2010
Merz Pharmaceuticals, a privately-held producer of pharmaceuticals and beauty products, has agreed to acquire medical aesthetics company BioForm Medical Inc for $253 million.
Merz, based in Frankurt, Germany, will pay $5.45 per BioForm share, a premium of 60 per cent to the company's closing price on Thursday.
Merz manufactures and sells innovative drugs in the areas of neurology and psychiatry, dermatology and metabolism. It is a leader in treating Alzheimer's, Parkinson's and depression, and has made rapid advances in anti-ageing skin care.
Merz's flagship molecule is Memantine, an active ingredient used to treat moderate-to-severe Alzheimer's dementia symptoms. Memantine is sold under Merz's own brand name Azura, and is licensed to Forest Laboratories and Lundbeck.
In the fiscal year 2008-09, Merz had revenue of €589.8 million ($828.7 million) and 40 per cent of this was generated from outside of Germany.
San Mateo, California-based BioForm Medical is a medical aesthetics company, which develops products that enhance aesthetic procedures performed in dermatology and plastic surgery practices.
.jpg "RBI keeps repo rate unchanged as focus remains on inflation")
.jpg "Indian Oil, Panasonic team up for lithium-ion cell production in India")
